Показано 0 из 0
Дата |
---|
17:41 |
02.05.2024 |
30.04.2024 |
29.04.2024 |
26.04.2024 |
25.04.2024 |
24.04.2024 |
23.04.2024 |
22.04.2024 |
19.04.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
8.86
|
9.88
|
8.10
|
8.10
|
8.78
|
8.78
|
|
|
|
|
8.10
|
10.40
|
8.18
|
8.18
|
8.86
|
8.86
|
|
|
|
|
8.18
|
10.50
|
8.22
|
8.22
|
8.94
|
8.84
|
|
|
|
|
8.22
|
10.55
|
7.96
|
7.96
|
8.96
|
8.90
|
|
|
|
|
7.96
|
10.25
|
7.96
|
7.96
|
8.60
|
8.56
|
|
|
|
|
7.96
|
10.25
|
7.74
|
7.74
|
8.36
|
8.36
|
|
|
|
|
7.74
|
9.94
|
7.68
|
7.68
|
8.36
|
8.36
|
|
|
|
|
7.68
|
9.86
|
7.76
|
7.76
|
8.36
|
8.36
|
|
|
|
|
7.76
|
9.96
|
7.66
|
7.66
|
8.30
|
8.26
|
|
|
|
|
7.66
|
9.84
|
7.86
|
7.86
|
8.54
|
8.54
|
|
|
|
|
MaaT Pharma is specialized in the research and development of microbiome biotherapies for use in the treatment of solid cancer tumors. The company has a portfolio of 2 products in clinical development, including 1 in Phase II (MaaT013 for the treatment of acute graft-versus-host disease) and 1 in Phase Ib (MaaT033 for the prevention of complications of allogeneic hematopoietic stem cell transplantation), and 1 product in preclinical development (MaaT03X for the improvement of the response to immune checkpoint inhibitors in various types of solid tumors).